Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with advanced solid tumors.

被引：1
|
作者：
Lopez, Juanita Suzanne
Plummer, Elizabeth Ruth
Devlin, Michael-John
Rulach, Robert
Garces, Alvaro Henrique Ingles
Haris, Noor R. Md
Miller, Rowan
Crawford, Donna
D'Arcangelo, Manolo
Aversa, Caterina
Hannah, Alison L.
Anderson, Stephanie
Engelhardt, Marc Frederick
Kaindl, Thomas
Larger, Patrice
Bachmann, Felix
Lane, Heidi A.
McKernan, Phil
Evans, T. R. Jeffry
Kristeleit, Rebecca Sophie
机构：
[1] Royal Marsden Hosp, Sutton, Surrey, England
[2] Inst Canc Res, Sutton, Surrey, England
[3] Freeman Rd Hosp, Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England
[4] Univ Coll London Hosp, London, England
[5] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[6] UCL, Canc Inst, London, England
[7] Oncol Clin Trial Consulting, Sebastopol, CA USA
[8] Basilea Pharmaceut Int Ltd, Basel, Switzerland
[9] Univ Glasgow, Glasgow, Lanark, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2530
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2530
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors
    Pearson, Andrew D. J.
    Federico, Sara M.
    Aerts, Isabelle
    Hargrave, Darren R.
    DuBois, Steven G.
    Iannone, Robert
    Geschwindt, Ryan D.
    Wang, Ruixue
    Haluska, Frank G.
    Trippett, Tanya M.
    Geoerger, Birgit
    ONCOTARGET, 2016, 7 (51): : 84736 - 84747
  • [32] A phase 1 study of serplulimab, a novel humanized monoclonal anti-PD-1 antibody, in patients with advanced solid tumors.
    Ho, Ching-Liang
    Chao, Tsu-Yi
    Chang, Chia Lun
    Lin, Hsuan-Yu
    Yang, Futang
    Wang, Qingyu
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] ProGem1: Phase I first-in-human study of the novel nucleotide NUC-1031 in adult patients with advanced solid tumors.
    Ghazaly, Essam Ahmed
    Joel, Simon
    Gribben, John G.
    Mohammad, Tariq
    Emiloju, Oluwadunni
    Stavraka, Chara
    Hopkins, Tom
    Gabra, Hani
    Wasan, Harpreet
    Habib, Nagy A.
    Leonard, Robert C. F.
    McGuigan, Christopher
    Slusarczyk, Magdalena
    Blagden, Sarah Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors.
    Patel, Manish R.
    Fakih, Marwan
    Olszanski, Anthony J.
    Lockhart, Albert C.
    Drilon, Alexander E.
    Fu, Siqing
    Bazhenova, Lyudmila
    Patel, Rupal
    Oliver, Jennifer W.
    Multani, Pratik S.
    Wang, Ding
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] A clinical, pharmacodynamic and pharmacokinetic phase I study of SCH 66336 (SCH) an oral inhibitor of the enzyme farnesyl transferase given once daily in patients with solid tumors.
    Awada, A
    Eskens, F
    Piccart, MJ
    Van der Gaast, A
    Bleiberg, H
    Cutler, DL
    Fumoleau, P
    Wanders, J
    Faber, MN
    Verweij, J
    CLINICAL CANCER RESEARCH, 1999, 5 : 3733S - 3733S
  • [36] A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.
    Rasco, Drew W.
    Lakhani, Nehal J.
    Li, Yufeng
    Men, Lichuang
    Wang, Hengbang
    Ji, Jiao
    Tang, Yuefen
    Liang, Zhiyan
    Amaya, Alex
    Estkowski, Kathy
    Sun, Joan
    Huang, Yingjie
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] A phase 1 study of AR-42 in patients with advanced solid tumors, including nervous system tumors.
    Valencia, Hugo
    Newton, Herbert B.
    Hade, Erinn
    Sborov, Douglas Weston
    Cavaliere, Robert
    Poi, Ming
    Phelps, Mitch
    Wang, Jiang
    Coss, Christopher C.
    Khountham, Soun
    Monk, Paul
    Olencki, Thomas
    Shapiro, Charles L.
    Piekarz, Richard
    Hofmeister, Craig C.
    Grever, Michael R.
    Welling, D. Bradley
    Mortazavi, Amir
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [38] A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.
    Xu, Ruihua
    Li, Yuhong
    Ji, Jiao
    Qiu, Miaozhen
    Zhang, Yang
    Liu, Wenqin
    Tian, Xiaohong
    Li, Su
    Wang, Hengbang
    Wang, Fenghua
    Zhang, Dongsheng
    Wang, Feng
    Wang, Zhiqiang
    Luo, Huiyan
    Zou, Benyan
    Wang, De shen
    Ren, Chao
    Jin, Ying
    Zhai, Yifan
    Yang, Dajun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] Phase 1/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors.
    Parikh, Aparna Raj
    Radojcic, Vedran
    Clancy, Myles
    Brouwer, Susan
    Kushwaha, Shaliny
    Huang, Yifan
    Gabrail, Nashat
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS227 - TPS227
  • [40] A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.
    Kristeleit, Rebecca Sophie
    Shapiro, Geoffrey
    LoRusso, Patricia
    Infante, Jeffrey R.
    Flynn, Michael
    Patel, Manish R.
    Tolaney, Sara M.
    Hilton, John Frederick
    Calvert, Alan Hilary
    Giordano, Heidi
    Isaacson, Jeffrey D.
    Borrow, Jennifer
    Allen, Andrew R.
    Jaw-Tsai, Sarah S.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345